Terms of useSchering Corporation invites residents of the United States to access and use this Internet site subject to the terms and conditions below and all applicable laws. This site and all information contained therein are intended for access and use by such residents only. The entire content of this site is subject to copyright protection. Copyright© 2008, Schering Corporation, Kenilworth, NJ 07033. All rights reserved. You may download and retain on your disk or in hard copy form a single copy of material published on this site for your personal use, provided that you do not remove any proprietary notices. You may not otherwise copy, distribute, display, download, modify, or repost all or part of any material without Schering Corporation's written permission. You may not mirror on another Web server all or part of any material published by Schering Corporation on this site, and you may not inline any of the graphics contained in any material published on this site. Schering Corporation will use reasonable efforts to include accurate and up-to-date information on this site, but makes no representations or warranties as to its accuracy or completeness. Access to and use of the content is at your own risk, and neither Schering Corporation nor any party involved in creating or delivering this site shall be liable to you for any damage of any kind arising out of your access, use or inability to access or use this site, or for any omissions or errors in its content. Schering Corporation reserves the right to alter or delete material from this site at any time. Schering Corporation may revise these terms and conditions periodically. Follistim® AQ (follitropin beta injection) is approved to help women who have problems with ovulation. Follistim® AQ will not help women whose ovaries do not work at all (primary ovarian failure). Follistim® AQ is also for women that are in an assisted reproductive technology (ART) program, such as in vitro fertilization. Important Safety Information: Always follow your health care professional’s dosing instructions when administering Follistim® AQ Cartridge. Your health care professional has individualized the dose to be administered based on your medical history. Do not change your dose unless instructed by your health care professional. Do not use Follistim® AQ if you are allergic to recombinant human FSH products; have primary ovarian failure (your ovaries do not work at all); are pregnant or think you might be pregnant; have uncontrolled thyroid or adrenal gland problems; have tumors in your ovaries, breasts, uterus, hypothalamus, or pituitary gland; have heavy or irregular vaginal bleeding and the cause is not known; have ovarian cysts or enlarged ovaries not due to polycystic ovary syndrome (PCOS); or are allergic to streptomycin or neomycin. Follistim® AQ may contain traces of these antibiotics and may cause allergic reactions. Follistim® AQ may cause ovarian hyperstimulation syndrome (OHSS), which is a serious medical problem that can happen when the ovaries are overstimulated. In rare cases it has caused death. OHSS causes fluid to build up suddenly in the stomach and chest areas. OHSS may occur after treatment with Follistim® AQ. Call your health care professional right away if you get any of the following symptoms: severe pelvic pain (lower stomach area), nausea, vomiting, sudden weight gain, or reduced urine output. Follistim® AQ and other FSH products may cause serious lung problems including fluid in the lungs, trouble breathing, and worsening of asthma. Follistim® AQ and other FSH products may also cause blood clots in blood vessels. This can lead to blood vessel problems (thrombophlebitis), stroke, loss of limb, or a blood clot in the lung (pulmonary embolus). Follistim® AQ and other FSH products can cause multiple births. Your health care professional will discuss your chances of multiple births. Follistim® AQ should only be prescribed by physicians experienced in infertility treatments. Other side effects with Follistim® AQ include stomach pain, gas, pelvic pain, nausea, breast pain, injection site problems, enlarged stomach area, back pain, constipation, headache, and ovarian pain. If you get any side effects that concern you, call your health care professional. These are not all the side effects of Follistim® AQ. Contact your doctor or other health care professional without delay if you are experiencing symptoms including significant abdominal pain or if symptoms develop some days after the last injection has been given. Please click here for important Product Information on Follistim® AQ Cartridge. Please click here for important Product Information on Follistim® AQ Vial. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. Pregnyl® (chorionic gonadotropin for injection, USP) is approved to induce ovulation and pregnancy in women who have problems with ovulation and who have been appropriately pretreated with human menopausal gonadotropins (medications containing follicle-stimulating hormone [FSH] and luteinizing hormone [LH]). Pregnyl® will not help women whose ovaries do not work at all (primary ovarian failure).
Important Safety Information:
Pregnyl® should be used in conjunction with human menopausal gonadotropins. Pregnyl® should only be prescribed by physicians experienced in infertility treatments. Pregnyl® may cause ovarian hyperstimulation syndrome (OHSS), which is a serious medical problem that can happen when the ovaries are overstimulated. In rare cases it has caused death. OHSS causes fluid to build up suddenly in the stomach and chest areas. OHSS may occur after treatment with Pregnyl®. Call your health care professional right away if you get any of the following symptoms: severe pelvic pain (lower stomach area), nausea, vomiting, sudden weight gain, or reduced urine output. Pregnyl® may also cause rupture of ovarian cysts resulting in internal bleeding (hemoperitoneum), multiple births, and artery blockage by a blood clot (arterial thromboembolism). Other side effects with Pregnyl® include headache, irritability, restlessness, depression, fatigue, edema, and pain at the site of injection. If you get any side effects that concern you, call your health care professional. Please click here for important Product Information. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. Ganirelix Acetate Injection is approved for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.
Important Safety Information:
Ganirelix Acetate Injection should only be prescribed by physicians experienced in infertility treatments. Before starting treatment with Ganirelix, pregnancy must be excluded. Hypersensitivity (allergic) reactions, some severe, have been reported after the first dose of Ganirelix Acetate Injection. Call your health care professional right away if you get any of the following symptoms: hives, difficulty breathing, chest tightness, high or low blood pressure, vomiting, or diarrhea. The packaging of this product contains natural rubber latex which may cause allergic reactions. Ganirelix Acetate Injection may cause ovarian hyperstimulation syndrome (OHSS), which is a serious medical problem that can happen when the ovaries are overstimulated. In rare cases it has caused death. OHSS causes fluid to build up suddenly in the stomach and chest areas. Call your health care professional right away if you get any of the following symptoms: severe pelvic pain (lower stomach area), nausea, vomiting, sudden weight gain, or reduced urine output. Other side effects with Ganirelix Acetate Injection include abdominal pain, death of unborn child, headache, vaginal bleeding, injection site reaction, and nausea. If you get any side effects that concern you, call your health care professional. Please click here for important Product Information. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. |
|